anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: organic chemistry, chemical technology, medicine, gastroenterology, pharmacy. SUBSTANCE: invention relates to a novel method for preparing omeprazole that is effective inhibitor of gastric acid secretion and useful as an anti-ulcerous agent. Invention describes method for preparing omeprazole including oxidation step of 5- methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl] thio]-1H-benzimidazole in organic solvent with an oxidizing agent and, possibly, in the presence of a base. Oxidation is carried out in the presence of titanium complex. Invention provides the development of novel, more suitable and effective method for preparing racemic omeprazole. EFFECT: improved preparing method. 10 cl, 2 ex
Metformin pills will be given orally and daily during the 2-week recovery period following single leg immobilization Metformin will be titrated up to a dose 2g/day. 1g dose (two 500 mg pills) will be taken in the morning and a 1g dose will be taken in the evening. This will take place over each day for 14 days during the recovery period.
Background: A midwife-led continuity model of care was implemented in governmental maternal facilities in Palestine. Midwives from the hospitals provided outreaching caseload ante- and postnatal care to women in rural villages clinics and homes. This study investigated if the model had impact on important maternal and neonatal health outcomes.

Method: A retrospective cohort design was used. Nablus governmental hospital, Rafidia's medical records were reviewed and data extracted involving 2199 women with singleton pregnancies, residing in rural villages, and their new-born babies born between January 2016 and February 2017. Outcomes were limited to the available information in the hospital's birth registry. Important maternal outcomes were postpartum anaemia (Hb \<11), mode of delivery and induction of labour. Important outcomes for new-borns were premature delivery \< 37 weeks, birth weight \< 2500g and 1500g and referral to neonatal intensive care unit. Outcomes were compared between women receiving the midwife-led continuity model of antenatal care and women receiving regular care.
<P>PROBLEM TO BE SOLVED: To provide an external preparation for skin which utilizes a natural product and can be used safely, giving tension to the skin, preventing skin disease dermatosis, having higher skin beautifying effect and anti-aging effect, etc.  <P>SOLUTION: The external preparation for skin is composed of appropriately formulated Folium Rhododendron anthopogonoises and honey, and contains components which give tension to the skin, improve skin function and prevent skin disease. The extract from the folium Rhododendron anthopogonoises contains components which suppress sebum, smell of aged person, itching, dandruff, head sebum, etc. The extract from the folium Rhododendron anthopogonoises is a component at least soluble in either one of water or alcohol. The extract from the folium Rhododendron anthopogonoises is formulated in a cream or a pack preparation or in a gel of the poultice preparation.  <P>COPYRIGHT: (C)2008,JPO&INPIT
While waiting for coronary artery bypass graft (CABG) surgery many patients receive little if any medical and nursing input, at a time which is very stressful for them and their families. This randomised controlled trial will test whether a home-based, nurse-led support and education programme for patients waiting for such surgery can optimise mental and physical fitness and improve coronary heart disease risk factors by addressing anxiety, hypertension, obesity, diabetes and serum cholesterol in the waiting period. Patients will be followed up in their own homes monthly by a cardiac nurse and given lifestyle advice and information to prepare them for surgery. Primary outcome measurements will be anxiety, length of stay, blood pressure, cholesterol, blood glucose, smoking and body mass index. Secondary outcomes will be quality of life, and post-operative complications. Economic analysis and qualitative assessment of patients' opinion of the programme will also be performed.
Arm 1 will receive DAA medication at the second appointment following the return of RNA HCV results. They will receive sofosbuvir (400mg) and velpatasvir (100mg).
FIELD: food industry, particularly, methods of medicinal herbs processing with preparation from them of biologically active additives in the form of pastes. SUBSTANCE: proposed are methods of medicinal herbs processing including extraction. Nettle powder with particles dispersity of 200-400 mcm is used as raw material in extraction. Simultaneously with extraction, grinding of nettle powder is conducted up to particles size of 20-30 mcm. Extraction process is carried out by 96-deg ethyl alcohol (ratio of powder : alcohol is 1:2.0-1:2.5) at temperature of 25-30 C for 12-16 min. Extraction of nettle powder may be conducted by sunflower-seed oil (ratio of powder : oil is 1:2.0-1:2.5) at temperature of 70-80 C for 30-35 min. It is possible combined extraction of raw material with 96-deg ethyl alcohol and sunflower-seed oil (ratio of powder:alcohol:oil is 1:1.2.1.2-1:1.5:1.5) at temperature of 40-50 C for 20-25 min without phases separation. EFFECT: increased extraction efficiency and yield of biologically active substance at preparation of ready-to-use half-finished products in the form of pastes from nettle powder. 3 cl, 1 tbl, 12 ex
This is a randomized controlled trial which will include patients with obesity undergoing bariatric surgery. The patients will be randomly allocated into two groups: transversus abdominis plane block group and erector spinae plane block group. The block will be performed after induction of general anesthesia. Preoperative evaluation and preparation will include history-taking, laboratory investigation, fasting recommendations, and optimization of the medical status. The two groups will receive standard induction and maintenance of anesthesia. After the end of the operation, patients will receive standard care according to the local protocols and the enhanced recovery recommendations. Patients will be monitored according to the pain-related outcomes as well as hemodynamic parameters.
In this study, we developed a composite hydrogel based on Gellan gum containing Boswellia serrata extract (BSE). BSE was either incorporated directly or loaded into an MgAl-layered double hydroxide (LDH) clay to create a multifunctional cartilage substitute. This composite was designed to provide anti-inflammatory properties while enhancing chondrogenesis. Additionally, LDH was exploited to facilitate the loading of hydrophobic BSE components and to improve the hydrogel's mechanical properties. A calcination process was also adopted on LDH to increase BSE loading. Physicochemical and mechanical characterizations were performed by spectroscopic (XPS and FTIR), thermogravimetric, rheological, compression test, weight loss and morphological (SEM) investigations. RPLC-ESI-FTMS was employed to investigate the boswellic acids release in simulated synovial fluid. The composites were cytocompatible and capable of supporting the mesenchymal stem cells (hMSC) growth in a 3D-conformation. Loading BSE resulted in the modulation of the pro-inflammatory cascade by down-regulating COX2, PGE2 and IL1β. Chondrogenesis studies demonstrated an enhanced differentiation, leading to the up-regulation of COL 2 and ACAN. This effect was attributed to the efficacy of BSE in reducing the inflammation through PGE2 down-regulation and IL10 up-regulation. Proteomics studies confirmed gene expression findings by revealing an anti-inflammatory protein signature during chondrogenesis of the cells cultivated onto loaded specimens. Concluding, BSE-loaded composites hold promise as a tool for the in-situ modulation of the inflammatory cascade while preserving cartilage healing.
Dilantin can cause rare, serious skin adverse events such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. Although serious skin reactions may occur without warning, patients should be alert for the signs and symptoms of skin rash and blisters, fever, or other signs hypersensitivity such as itching, and should seek medical advice from their physician immediately when observing any indicative signs or symptoms. The physician should advise the patient to discontinue treatment if the rash appears (see WARNINGS section regarding drug discontinuation). If the rash is of a milder type (measles-like or scarlatiniform), therapy may be resumed after the rash has completely disappeared. If the rash recurs upon reinstitution of therapy, further Dilantin medication is contraindicated. Published literature has suggested that there may be an increased, although still rare, risk of hypersensitivity reactions, including skin rash, SJS, TEN, hepatotoxicity, and Anticonvulsant Hypersensitivity Syndrome in black patients.

Studies in patients of Chinese ancestry have found a strong association between the risk of developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant of the HLA B gene, in patients using another anticonvulsive drug. Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Asian ancestry taking drugs associated with SJS/TEN, including phenytoin. Consideration should be given to avoiding use of drugs associated with SJS/TEN, including Dilantin, in HLA-B*1502 positive patients when alternative therapies are otherwise equally available.
The invention discloses medicine for treating avian influenza. The medicine is prepared from, by weight, 5-10 parts of herba ephedrae, 8-12 parts of radix bupleuri, 20-30 parts of honeysuckles, 5-10 parts of cortex phellodendri chinensis, 10-20 parts of Chinese magnoliavine fruit, 8-12 parts of rhizoma coptidis, 5-8 parts of cyrlomium pachyphyllum. (resenst).C. chr, 1-3 parts of rhizoma acori graminei, 5-8 parts of folium isatidis, 5-10 parts of mangifera indica leaves, 5-8 parts of cochin china momordica seeds, 13-18 parts of fried radix scutellariae, 8-12 parts of  rhizoma phragmitis, 8-12 parts of rhizoma atractylodis, 4-6 parts of stems of falsenettleleaf pepper, 3-6 parts of porana flowers, 180-220 parts of rimantadine, 45-55 parts of paracetamol, 0.01-0.02 part of dexamethasone, 580-650 parts of anhydrous sodium sulphate and 140-160 parts of  glucose powder. The medicine is an artificial synthesized antiviral agent, virus proliferation is inhibited by stopping viruses from entering host cells and restraining virus replication, and the antiviral effect is achieved. The medicine is orally taken, absorption is fast and full, the medicine is discharged with urine in an original shape, residue is avoided, and the medicine has the special effect of preventing and treating infectious disease caused by viruses. Compared with that of amantadine, the adverse reaction occurrence rate is low.
Apparatus and method are provided to collect and analyze phonocardiogram (PCG) an electrocardiogram (ECG) waveforms. In one novel aspect, the PCG and ECG waveforms are collected from wearable devices. In one embodiment, the wearable device collects heartbeat waveforms by attaching the device to the patient for a long period and sends the collected waveforms to a receiver through a wireless network. In one embodiment, an acoustic seal layer is attached to the wearable device to reduce the body movement noises and environmental noises. In another novel aspect, an analysis method compares received patient's current PCG/ECG waveform with historic data. In one embodiment, the historic data are stored in a cloud-based database.
PURPOSE:A complex pharmaceutical, obtained by laminating a filmy holding material containing a percutaneous absorption promoter and drug on an adhesive surface of an adhesive layer containing a drug on a support leaving a sufficient area to obtain the skin adhesion function of the adhesive surface and having both rapid acting and long acting properties. CONSTITUTION:A complex pharmaceutical obtained by laminating a filmy holding material containing a percutaneous absorption promoter and a drug on an adhesive surface of an adhesive layer containing a drug and laminated on one surface of a support leaving a sufficient area to keep the skin adhesion function of the adhesive surface. After application to the skin, a large amount of the drug is released by the promoter, and the rapid acting property can be expected. Since the adhesive layer containing the drug closely adheres and fixes the complex pharmaceutcal on the skin surface, supplies the drug from the exposed adhesive surface to the skin by the diffusion and migration of the contained drug to the skin and filmy holding material. Thereby, the long acting property can be expected. The filmy holding material is preferably a porous film, and preferably laminated on the central part of the adhesive surface to leave the adhesive surface on the peripheral part thereof.
The invention discloses a proved recipe for treating ascites. Abnormal liquid symptoms are caused in the enterocoelia, and ascites, also known as tympanites, can be used by heart and kidney diseases and diseases in the enterocoelia. A patient with ascites only and without edema on other parts of the body is often suffered from cirrhosis (cirrhosis due to schistosomiasis is considered at the first in a schistosomiasis infected area, and a patient with history of jaundice is considered to be suffered from cirrhosis caused by hepatitis). The ascites has the symptom of generalized edema and is commonly seen in acute and chronic nephritis, cardiac failure and the like. The proved recipe for treating ascites is repeatedly researched in many years and is practiced again and again on the basis that numerical ascites patients are cured due to research and review of clinical specialists within more than ten years, the complications can be effectively eliminated from the diseases in the heart, kidneys and enterocoelia, and the latest formula is developed. The proved recipe for treating ascites takes pure traditional Chinese medicines as raw materials, juice is extracted through a traditional decoction method for oral administration, and the proved recipe suits the remedy to the case according to the pathogenesis, does not have a toxic or side effect and is unique in treatment effect, short in course of treatment, quick-acting and high in consolidation.
Barley yellow dwarf viruses (BYDVs) cause widespread damage to global cereal crops. Here we report a novel strategy for elevating resistance to BYDV infection. The 17K protein, a potent virulence factor conserved in BYDVs, interacted with barley IMP-α1 and -α2 proteins that are nuclear transport receptors. Consistently, a nuclear localization signal was predicted in 17K, which was found essential for 17K to be transported into the nucleus and to interact with IMP-α1 and -α2. Reducing HvIMP-α1 and -α2 expression by gene silencing attenuated BYDV-elicited dwarfism, accompanied by a lowered nuclear accumulation of 17K. Among the eight common wheat CRISPR mutants with two to four TaIMP-α1 and -α2 genes mutated, the triple mutant α1aaBBDD /α2AAbbdd and the tetra-mutant α1aabbdd /α2AAbbDD displayed strong BYDV resistance without negative effects on plant growth under field conditions. The BYDV resistance exhibited by α1aaBBDD /α2AAbbdd and α1aabbdd /α2AAbbDD was correlated with decreased nuclear accumulation of 17K and lowered viral proliferation in infected plants. Our work uncovers the function of host IMP-α proteins in BYDV pathogenesis and generates the germplasm valuable for breeding BYDV-resistant wheat. Appropriate reduction of IMP-α gene expression may be broadly useful for enhancing antiviral resistance in agricultural crops and other economically important organisms.
Primary angle closure disease (PACD) is a major cause of blindness worldwide. It has a high prevalence in East Asia, especially in China, which leads to a higher incidence of blindness than open-angle glaucoma. The aim of this study was to directly observe the circumlental space (CLS) in laser peripheral iridotomized eyes with PACD and to determine whether this structure plays a role in the pathogenesis of PACD. Fifty eyes of 50 patients with PACD, who had received laser peripheral iridotomy performed with neodymium:yttrium-aluminum-garnet were recruited from glaucoma clinics from March 2021 to May 2022, including 17 primary angle closure suspect (PACS), 16 primary angle closure (PAC) and 17 primary angle closure glaucoma (PACG). They were classified into two groups based on whether the ciliary process and the crystalline lens equator were in contact using slit-lamp photograph: the attached group and the unattached group. The demographic, clinical characteristics and anterior segment parameters measured from ultrasound biomicroscopy were compared between the attached group and the unattached group. Thirty-three eyes were assigned to the attached group and 17 eyes belonged to the unattached group. In the unattached group, the mean CLS was 0.10 ± 0.07 mm. No significant differences were identified between the different diagnosis groups in age, sex, best-corrected visual acuity, intraocular pressure, white-to-white, axial length, central corneal thickness, anterior chamber depth, flat keratometry, steep keratometry or iridotomy diameter (p > 0.05). The unattached group had shorter trabecular-ciliary process distance (p = 0.021) and larger ciliary process area (p = 0.001) compared with the attached group. Small CLS and its potential effect (partial ciliary block) might be considered as one of the mechanisms of PACD.
Sequential hemodialysis treatment study in which all enrollees move through four (4) separate treatment phases. Results from the separate phases will be compared to standard bicarbonate dialysis with standard does of heparin.
Past studies have shown that combination therapies not only will result in better clinical outcomes but may prolong the effects of therapy. The enhanced effects seen with combination therapies are likely related to a greater suppression of HIV replication and alterations in resistance patterns. Both in vitro and in vivo studies suggest that triple-drug therapy may have an advantage over one- and two-drug regimens. Therefore, triple-drug therapy appears to be an important strategy in the treatment of HIV infection.

This is a Phase II, randomized, controlled, open-label trial of NFV + SQVsgc and either DLV or combined 3TC/ZDV versus NFV and combined 3TC/ZDV. Prior to randomization, patients are stratified by HIV RNA (above or below 65,000 copies/ml) and by prior antiretroviral therapy (no therapy vs any therapy). Patients (100 patients/arm) are then randomly assigned to one of four arms. Arm I receives NFV plus combination 3TC/ZDV. Arm II receives NFV plus SQVsgc plus combination 3TC/ZDV. Arm III receives NFV plus SQVsgc plus DLV. Arm IV receives NFV plus SQVsgc plus DLV. Treatment continues for 48 weeks following enrollment of the last patient. Response to treatment is assessed at week 16. Patients with confirmed plasma HIV RNA levels \>= 500 copies/ml at week 16 whose plasma HIV RNA has decreased since study entry (day 0) may continue therapy and be reassessed at weeks 20 and 24. Patients considered treatment failures (i.e., 2 consecutive plasma HIV RNA levels \>= 500 copies/ml at or after week 16) or who have relapsed may register to Step 2 treatment (addition of at least 2 new drugs to their prior treatment regimen), enroll in another ACTG protocol at time of failure, or seek the best available therapy while continuing to be followed for remainder of study.
A system is provided that identifies a cohort. The system retrieves metadata that includes information about one or more data fields of a data source. The system further creates a query for the data source based on the retrieved metadata. The system further compiles the query and executes the query on the data source. By executing the query on the data source, the system creates a case series. The system further generates a report based on the case series.
Inhibitors of the transforming growth factor-β (TGF-β) pathway are potentially promising antifibrotic therapies, but nonselective simultaneous inhibition of all three TGF-β homologs has safety liabilities. TGF-β1 is noncovalently bound to a latency-associated peptide that is, in turn, covalently bound to different presenting molecules within large latent complexes. The latent TGF-β-binding proteins (LTBPs) present TGF-β1 in the extracellular matrix, and TGF-β1 is presented on immune cells by two transmembrane proteins, glycoprotein A repetitions predominant (GARP) and leucine-rich repeat protein 33 (LRRC33). Here, we describe LTBP-49247, an antibody that selectively bound to and inhibited the activation of TGF-β1 presented by LTBPs but did not bind to TGF-β1 presented by GARP or LRRC33. Structural studies demonstrated that LTBP-49247 recognized an epitope on LTBP-presented TGF-β1 that is not accessible on GARP- or LRRC33-presented TGF-β1, explaining the antibody's selectivity for LTBP-complexed TGF-β1. In two rodent models of kidney fibrosis of different etiologies, LTBP-49247 attenuated fibrotic progression, indicating the central role of LTBP-presented TGF-β1 in renal fibrosis. In mice, LTBP-49247 did not have the toxic effects associated with less selective TGF-β inhibitors. These results establish the feasibility of selectively targeting LTBP-bound TGF-β1 as an approach for treating fibrosis.
OBJECTIVES: Vasomotor symptoms (VMS), including hot flashes and night sweats, are hallmark symptoms of the menopause transition. Previous research has documented greater frequency, duration, and severity of VMS in Black women compared with women from other racial/ethnic groups, even after accounting for other factors. This analysis examined the association between discrimination and VMS and the extent to which discrimination accounts for the disproportionate burden of VMS in Black women.
METHODS: Using available discrimination and VMS data from the SWAN cohort study (n = 2,377, 48% White, 32% Black, 6% Japanese, 4% Chinese, and 9% Hispanic women) followed approximately yearly in midlife from premenopause (42-52 y) through postmenopause (~20 y), we assessed concurrent associations between discrimination and VMS frequency in the past 2 weeks using weighted generalized mixed models. We also assessed associations between chronic discrimination across first four visits and VMS trajectories from premenopause to postmenopause using weighted multinomial logistic regression. Models were adjusted for known risk factors for VMS.
RESULTS: Higher levels of discrimination were associated with concurrent reporting of any (odds ratio [OR], 1.57 [1.31-1.89]) and frequent (≥6 d) VMS (OR, 1.55 [1.21-1.99]). After adjustment, associations remained significant for any (OR, 1.30 [1.09-1.54]) but not frequent VMS. For any VMS trajectories, chronic discrimination was associated with "continuously high" (OR, 1.69 [1.03-2.77]) and "high pre-FMP-decline post-FMP" (OR, 1.70 [1.01-2.88]) versus "FMP-onset low" trajectories. After adjusting for discrimination, odds of reporting any, frequent, and of being in the "continuously high" any VMS trajectory remained elevated for Black versus White women.
CONCLUSIONS: Discrimination is associated with greater concurrent risk of any (but not frequent) VMS, and chronic discrimination is associated with a continuously high reporting of any VMS over time, independent of known risk factors. Adjusting for discrimination attenuates but does not eliminate the increased risk of VMS for Black women.
Participants in this arm will complete baseline and follow-up visits (approximately 3-months after) and Mid-intervention safety checks. They will attend the in the Mindfulness-Based Training program that will meet weekly for 8 weeks. Each session will last approximately one-and-a-half hours.